Title: Erlotinib - a key drug for targeted treatment of non-small cell lung cancer

First paragraph: content overview
Erlotinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor mainly used to treatLocally advanced or metastatic non-small cell lung cancer (NSCLC), especially for EGFR mutation-positive patients. Its core mechanism is to inhibit tumor cell proliferation by blocking the EGFR signaling pathway. The main contents include:Drug mechanism, indications, clinical efficacy, manufacturer and precautions. The focus is on its targeting, applicable groups and safety.

Paragraph 2: Drug mechanism and indications
Erlotinib blocks the growth signaling of tumor cells by selectively binding to the tyrosine kinase domain of the intracellular region of EGFR. Clinical studies show that itEGFR exon19 deletion or L858R mutationThe effective rate for NSCLC patients can reach 60%-80%. Indications include: first-line treatment of EGFR mutation-positive NSCLC, and maintenance treatment or second-line treatment of advanced cases. Both the US NCCN guidelines and the Chinese CSCO guidelines recommend it as one of the standard treatment options.

Paragraph 3: Clinical efficacy and data support
Based on pivotal clinical trialsEURTACandOPTIMALStudies show that erlotinib significantly prolongs progression-free survival (PFS) in patients:

Research name	patient type	Median PFS
EURTAC	EGFR mutated NSCLC	9.7 months
OPTIMAL	Asian people	13.1 months

Common side effects are rash and diarrhea, which are usually controllable.

Paragraph 4: Manufacturer and medication precautions
Erlotinib is produced byRocheOriginal research, trade nameTarceva. Domestic generic drug companies includeBetta Pharmaceuticals (Kemena)Wait. Things to note when taking medication:Genetic testing confirms EGFR mutation;Avoid combined use with proton pump inhibitors;Regularly monitor liver function. In terms of financial burden, the monthly cost of the original drug is about 15,000 yuan (reduced to several thousand yuan after medical insurance negotiations).

Paragraph 5: Summary and Outlook
Erlotinib, as a representative drug of EGFR-TKI, has significantly improved the quality of life of certain lung cancer patients. In the future, we need to pay attention to resistance mechanisms (such as T790M mutation) and combination treatment strategies. Its precision medicine model provides a model for tumor treatment, but patients must strictly follow medical instructions and balance efficacy and safety.

Quote sources:
1. National Comprehensive Cancer Network (NCCN) Guidelines 2023 Edition
2. Chinese Society of Clinical Oncology (CSCO) Diagnosis and Treatment Guidelines for Non-Small Cell Lung Cancer 2022
3. Roche Pharmaceuticals Tarceva drug instructions
4. Zhou C, et al. Lancet Oncol. 2011 (OPTIMAL study)